A UCLA Health podcast with the sports medicine doctor on the peptide trend, and why he says the evidence in humans is still limited.
Recap by typeshit. Post by @uclahealthmedicallyspeaking on Instagram.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
21:08
A video on reaching a high protein target while keeping calories in check during GLP-1 treatment.
Loading…